Suppr超能文献

从埃及蜂胶中发现潜在黄嘌呤氧化酶抑制剂的综合策略及其与别嘌醇和非布索坦的协同作用。

Integrated - strategy for the discovery of potential xanthine oxidase inhibitors from Egyptian propolis and their synergistic effect with allopurinol and febuxostat.

作者信息

Ghallab Dina S, Shawky Eman, Metwally Ali M, Celik Ismail, Ibrahim Reham S, Mohyeldin Mohamed M

机构信息

Department of Pharmacognosy, Faculty of Pharmacy, Alexandria University Alexandria 21521 Egypt

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University Kayseri 38039 Turkey.

出版信息

RSC Adv. 2022 Jan 21;12(5):2843-2872. doi: 10.1039/d1ra08011c. eCollection 2022 Jan 18.

Abstract

Xanthine oxidase (XO) has been well-recognized as a validated target for the treatment of hyperuricemia and gout. Currently, there are two drugs in clinical use that shut down XO overactivity, allopurinol and febuxostat; however, detrimental side effects restrict their applications. Propolis is a unique natural adhesive biomass of structurally variable and biologically active metabolites that exert remarkable health benefits. Moreover, combination drug therapy has become a promising pharmacotherapeutic strategy directed for reformulating existing drugs into new combination entities with potentiating therapeutic impacts. In this study, computer-aided molecular docking and MD simulations accompanied by biochemical testing were used for mining novel pharmacologically active chemical entities from Egyptian propolis to combat hyperuricemia. Further, with a view to decrease the potential toxicity of synthetic drugs and enhance efficacy, propolis hits were subjected to combination analysis with each of allopurinol and febuxostat. More specifically, Glide docking was utilized for a structure-based virtual screening of in-house datasets comprising various Egyptian propolis metabolites. Rosmarinic acid, luteolin, techtochrysin and isoferulic acid were the most promising virtual hits. XO inhibitory assays demonstrated the ability of these hits to significantly inhibit XO in a dose-dependent manner. Molecular docking and MD simulations revealed a cooperative binding mode between the discovered hits and standard XO inhibitors within the active site. Subsequently, the most promising hits were tested in a fixed-ratio combination setting with allopurinol and febuxostat separately to assess their combined effects on XO catalytic inhibition. The binary combination of each techtochrysin and rosmarinic acid with febuxostat displayed maximal synergy at lower effect levels. In contrast, individually, techtochrysin and rosmarinic acid with allopurinol cooperated synergistically at high dose levels. Taken together, the suggested strategy seems imperative to ensure a steady supply of new therapeutic options sourced from Egyptian propolis to regress the development of hyperuricemia.

摘要

黄嘌呤氧化酶(XO)已被公认为是治疗高尿酸血症和痛风的有效靶点。目前,临床使用的两种药物可抑制XO的过度活性,即别嘌醇和非布司他;然而,有害的副作用限制了它们的应用。蜂胶是一种独特的天然粘性生物质,其结构多样且含有具有生物活性的代谢产物,具有显著的健康益处。此外,联合药物疗法已成为一种有前景的药物治疗策略,旨在将现有药物重新配方成具有增强治疗效果的新联合实体。在本研究中,通过计算机辅助分子对接和分子动力学(MD)模拟,并结合生化测试,从埃及蜂胶中挖掘新型药理活性化学实体以对抗高尿酸血症。此外,为了降低合成药物的潜在毒性并提高疗效,将蜂胶筛选出的活性成分与别嘌醇和非布司他分别进行联合分析。更具体地说,利用Glide对接对包含各种埃及蜂胶代谢产物的内部数据集进行基于结构的虚拟筛选。迷迭香酸、木犀草素、tectochrysin和异阿魏酸是最有前景的虚拟筛选结果。XO抑制试验表明,这些筛选结果能够以剂量依赖性方式显著抑制XO。分子对接和MD模拟揭示了所发现的筛选结果与活性位点内的标准XO抑制剂之间的协同结合模式。随后,将最有前景的筛选结果分别与别嘌醇和非布司他以固定比例组合进行测试,以评估它们对XO催化抑制的联合作用。每种tectochrysin和迷迭香酸与非布司他的二元组合在较低效应水平下显示出最大的协同作用。相比之下,单独使用时,tectochrysin和迷迭香酸与别嘌醇在高剂量水平下协同作用。综上所述,所建议的策略似乎势在必行,以确保稳定供应源自埃及蜂胶的新治疗选择,从而延缓高尿酸血症的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ca/8979054/ef431efb7b4b/d1ra08011c-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验